Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bioheart Inc announces update on phase I Adipose Stem Cell Trial


Monday, 5 May 2014 08:00am EDT 

Bioheart Inc:Announces an update on the phase I safety trial using adipose derived cells.Says in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell) in congestive heart failure patients.In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana.Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.This fat was processed to obtain the stromal vascular fraction (SVF) which contains mesenchymal stem cells, progenitor/endothelial cells, pericytes, hematopoetic stem cells and more.Patients were recently contacted to assess quality of life.Patients have reported that they are in good spirits and doing well.Most compelling data from this trial is the strong safety profile.All adverse events were adjudicated by an independent data safety monitoring board and deemed not related to the therapy. 

Company Quote

0.0242
-3.0E-4 -1.22%
18 Sep 2014